Adeona granted new US patent for oral tiomolibdate diammonium (Pharmaceutical Business Review)

Adeona granted new US patent for oral tiomolibdate diammonium (Pharmaceutical Business Review)
Adeona Pharmaceuticals, a developer of innovative drug candidates for the treatment of autoimmune and central nervous system diseases, has announced the issuance of US patent containing claims covering the use of thiomolybdates such as oral tiomolibdate diammonium for the treatment of Alzheimers disease.